Amisulpride: Progress and outcomes

Current Medical Research and Opinion

Volumn 18, Issue SUPPL. 3, 2002, Pages

  Lecrubier, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

amisulpride; antipsychotic; haloperidol; negative symptoms; positive symptoms; quality of life; risperidone; schizophrenia

Indexed keywords

DOPAMINE RECEPTOR; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; HUMAN; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; HUMANS; QUALITY OF LIFE; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 0036369582     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/030079902125001083     Document Type: Article

References (14)

1. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97
2. 3) as a target for neuroleptics. Nature 1990;347:146-51
3. 3 dopamine receptor antagonistic activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82
4. Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997; 132:396-401
5. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999;88: 107-17
6. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72
7. Rein W, Fleurot O, Turjanski S. Amisulpride improves affective symptoms in acute schizophrenia. In: Abstracts of the 11th Congress of the European College of Neuropsychopharmacology, Paris, France, 31 October-4 November 1998. European Neuropsychopharmacology 1998;8(Suppl 2):S231
8. Danion JM, Rein W, Fleurot O and the amisulpride study group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 1999;156:610-16
9. Loo H, Poirier-Littre M-F, Theron M, Rein A, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22
10. Colonna L, Saleem P et al. Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. International Clinical Psychopharmacology 2000;15:13-22
11. Carrière P, Bonhomme D, Lemperière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia. Eur Psychiatry 2000;15:321-29
12. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 2000;101:416-32
13. Lecrubier Y, Benkert O, Kasper S, et al. Amisulpride vs risperidone in schizophrenia: comparing clinical and functional outcome in a 6 month study. Presented at the ACNP 2000. Abstr. No 196
14. Csernansky JG, Mahmoud R, Brenner R, The Risperidone-USA-79 Study Group. A Comparison of risperidone and haloperidol for the prevention of relapse in patients with Schizophrenia. N Engl J Med 2002;346:16-22